<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="153467">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01102140</url>
  </required_header>
  <id_info>
    <org_study_id>IMPROVEHF</org_study_id>
    <nct_id>NCT01102140</nct_id>
  </id_info>
  <brief_title>The Impact of Pomegranate Extract on Chronic Cardiomyopathy Complicated by Renal Insufficiency (ImPrOVE): a Pilot Study</brief_title>
  <acronym>ImPrOVE</acronym>
  <official_title>The Impact of Pomegranate (Punica Granatum) Polyphenol Extract on Oxidative Stress, Ventricular Remodeling and Endothelial Function in Chronic Cardiomyopathy Complicated by Renal Insufficiency (ImPrOVE): a Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jennifer Cowger , MD, MS</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>POM Wonderful LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Michigan</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This blinded, controlled study will examine the impact of pomegranate polyphenol extract
      (POMx, from Pom Wonderful, LLC), 1000mg on cardiomyopathy in subjects with chronic renal
      insufficiency.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Heart failure (HF) is a disease of great prevalence in the U.S. with an associated high
      morbidity and mortality. In individuals with concomitant chronic renal insufficiency (CRI),
      outcomes are even worse due to pharmaceutical under treatment and higher baseline levels of
      oxidative stress. Reactive oxygen species (ROS) are generated during mechanoenergetic
      uncoupling and can cause myocardial protein, lipid, and DNA damage, leading to the
      development of HF. One means of preventing the progression of HF may be through ROS
      reduction or an improvement in systemic or local oxidative stress handling. In this
      randomized, single blind placebo-controlled pilot study, we hypothesize that 12 weeks of
      treatment with oral pomegranate extract (POMx) will lead to a reduction in oxidative stress
      (as assessed by measuring thiobarbituric acid-reactive substances, F8-isoprostanes, and
      glutathione) in subjects (n=30) with cardiomyopathy (LVEF ≤40%) and CRI (GFR &lt;60 ml/hr).
      Secondary aims include assessing the impact of POMx on myocardial remodeling and endothelial
      dysfunction by measuring serum collagen levels and asymmetric dimethylarginine,
      respectively. Findings from this study will serve as pilot data for a larger randomized
      trial of longer term POMx therapy in subjects with cardiomyopathy.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>July 2010</start_date>
  <primary_completion_date type="Anticipated">May 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single Blind (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>thiobarbituric reactive substances (TBARS)</measure>
    <time_frame>baseline and after 12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>F-8 isoprostanes</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>procollagen types I (PINP) and III (PIIINP)</measure>
    <time_frame>baseline and 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>asymmetric dimethylarginine (ADMA)</measure>
    <time_frame>baseline and 12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Cardiomyopathy</condition>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>POMx</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>15 subjects will received 1000 mg of oral POMx for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control- sugar Pill</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>15 subjects will receive a matching sugar pill for 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>POMx, pomegranate polyphenol extract</intervention_name>
    <description>1000 mg orally once daily.</description>
    <arm_group_label>POMx</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sugar Pill</intervention_name>
    <description>Matching sugar pill</description>
    <arm_group_label>Control- sugar Pill</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult subjects (≥21 years of age) with cardiomyopathy (ejection fraction ≤40%) of at
             least 1 year duration and CRI (GFR &lt;60 cc/hr for at least 3 months) will be eligible
             for enrollment.

          -  Subjects must have New York Heart Association (NYHA) functional class I-III symptoms
             and be on stable doses of HF evidence-based therapies (β-blocker, ACE inhibitor or
             ARBs, aldosterone inhibitor [if appropriate]) for at least 3 months or have a
             documented contraindication or intolerance to such therapy

        Exclusion Criteria:

          -  Subjects admitted to a hospital for acute myocardial infarction (defined as positive
             troponins) or HF exacerbation within the last 6 months will not be eligible for
             enrollment.

          -  Subjects on warfarin or rosuvastatin will also be excluded.

          -  Other exclusion criteria are as follows:

               -  HF that is deemed to be congenital or infiltrative in etiology

               -  the presence of a life-threatening illness with a projected survival ≤6 months;
                  ongoing infection

               -  pregnancy

               -  inability to follow-up

               -  end-stage renal disease requiring dialysis

               -  renal transplant listing

               -  recent (within last 6 months) POMx use or intake &gt;8 ounces daily of pomegranate
                  juice

               -  known hypersensitivity to any fruit in the Punicaceae family

               -  connective tissue or collagen vascular disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jennifer C Matthews, MD, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Univeristy of Michigan Health System</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bertram Pitt, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Michigan</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Joanna Wells</last_name>
    <phone>734 232-6383</phone>
    <email>joannamw@med.umich.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jennifer C Matthews, MD, MS</last_name>
    <phone>734 936-5265</phone>
    <email>jennmatt@umich.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Michigan Health Systems</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joanna Wells</last_name>
      <phone>734-232-6383</phone>
      <email>joannamw@med.umich.edu</email>
    </contact>
    <contact_backup>
      <last_name>Jennifer A Cowger, MD, MS</last_name>
      <phone>734 232 4154</phone>
      <email>jennmatt@med.umich.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University of Michigan Health System</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Jennifer A Cowger, MD, MS</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bertram Pitt, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2012</verification_date>
  <lastchanged_date>December 17, 2012</lastchanged_date>
  <firstreceived_date>April 12, 2010</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Michigan</investigator_affiliation>
    <investigator_full_name>Jennifer Cowger , MD, MS</investigator_full_name>
    <investigator_title>Assistant Professor, study PI</investigator_title>
  </responsible_party>
  <keyword>Cardiomyopathy</keyword>
  <keyword>Heart Failure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Cardiomyopathies</mesh_term>
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
